Maarten J. Van Der Doelen
Nijmegen, GE 6525GA, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
From Genomic Testing to Olaparib Treatment: Real-World Utilization and Outcomes in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer.
Journal: Drugs - real world outcomes
Published: March 10, 2026
Retreatment of Metastatic Castration-Resistant Prostate Cancer Patients with 223Ra Therapy in Daily Practice.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: March 05, 2025
Learning From Evidence: Changes in Real-World Use of Second Androgen Receptor Targeted Treatments in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Journal: Clinical genitourinary cancer
Published: December 03, 2024
Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients.
Journal: Theranostics
Published: February 01, 2024
The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of 223Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: September 10, 2023
Tumoral Ki67 and PSMA Expression in Fresh Pre-PSMA-RLT Biopsies and Its Relation With PSMA-PET Imaging and Outcomes of PSMA-RLT in Patients With mCRPC.
Journal: Clinical genitourinary cancer
Published: October 26, 2022
Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy.
Journal: Prostate cancer and prostatic diseases
Published: February 19, 2022
Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Journal: Frontiers in oncology
Published: February 26, 2021
Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer.
Journal: Prostate cancer and prostatic diseases
Published: February 18, 2021
Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223.
Journal: European journal of nuclear medicine and molecular imaging
Published: January 29, 2021
Response to comment on "Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer".
Journal: European journal of cancer (Oxford, England : 1990)
Published: October 30, 2020
Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy.
Journal: Urologic oncology
Published: September 24, 2020
Last Updated: 09/26/2026